基于整合网络和联合策略预测心肌梗死的新致病基因  

Prediction of the New Pathogenic Genes of Myocardial Infarction Based on Integrated Network and Joint Strategy

作　　者：吕亚娜[1] 陈丽娜[2] 徐晋[1] 李琬[2] 苗正强[2] 曲晓莉[2] 张思雅[2] 李为国 贾婿[2] 冯陈晨[2] 何月涵[2] 黄昊[2] 侯敏[2] 

机构地区：[1]哈尔滨医科大学基础医学院,黑龙江哈尔滨150081 [2]哈尔滨医科大学生物信息科学与技术学院,黑龙江哈尔滨150081

出　　处：《现代生物医学进展》2013年第4期613-619,共7页Progress in Modern Biomedicine

基　　金：黑龙江省教育厅基金(12511271);国家自然科学基金项目(61272388);黑龙江省自然科学基金(F201237);黑龙江省研究生创新科研资金(YJSCX2012-209HLJ);黑龙江大学创新基金(2012-011HYD)

摘　　要：目的:基于整合网络和联合策略预测心肌梗死的新致病基因。方法:从系统生物学的角度,提出基于蛋白质亚细胞定位信息,构建区域化的蛋白质互作的整合网络;通过疾病风险基因与已知致病基因的功能一致性程度和互作相关性的强度联合筛选的新策略,预测心肌梗死的新致病基因。结果:预测出10个心肌梗死的新致病基因(CCL19、CCL25、COMP、CCL11、CCL7、F2、KLKB1、HTR6、ADRB1、BDKRB2),其中8个基因(CCL19、CCL25、CCL11、CCL7、F2、KLKB1、ADRB1、BDKRB2)经文献证实与心肌梗死的发生发展有着密切的联系;另外2个基因(COMP、HTR6)尚需实验验证。结论:基于整合网络和联合策略预测出10个心肌梗死的新致病基因,此方法为探索复疾病的致病基因提供了新的思路,有助于阐明复杂疾病的致病机理。Objective： To predict the new pathogenic genes of myocardial infarction（MI） based on integrated network and joint strategy.Methods： An integrated regional protein-protein interaction network（PPIN） based on subcellular localization information of proteins from systems biology perspective was proposed.New pathogenic genes of MI were predicted from the new joint screening strategy of the degree of functional consistency and the strength of interaction correlation between risk pathogenic genes with known pathogenic genes.Results： 10 genes（CCL19,CCL25,COMP,CCL11,CCL7,F2,KLKB1,HTR6,ADRB1,BDKRB2） were predicted to be the new pathogenic genes for MI.Through literature confirmation,8 genes（CCL19,CCL25,CCL11,CCL7,F2,KLKB1,ADRB1,BDKRB2） were closely related to the development of MI.In addition,2 genes（COMP,HTR6） were still needed to be verified by further experiment.Conclusion： 10 genes for the prediction of new pathogenic genes of myocardial infarction were screened based on integrated network and joint strategy which provided additional insights for finding pathogenic genes and promoted to elucidate the pathogenesis of human complex diseases.

关 键 词：心肌梗死 蛋白质互作网络 亚细胞定位信息 功能一致性 

分 类 号：R542.22[医药卫生—心血管疾病] Q33[医药卫生—内科学]